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Abstract 21 
Microbial biofilms strongly resist host immune responses and antimicrobial treatments and are 22 
frequently responsible for chronic infections in peri-implant tissues. Biosurfactants (BSs) have recently 23 
gained prominence as a new generation of anti-adhesive and antimicrobial agents with great 24 
biocompatibility and were recently suggested for coating implantable materials in order to improve 25 
their anti-biofilm properties. 26 
In this study, the anti-biofilm activity of lipopeptide AC7BS, rhamnolipid R89BS and sophorolipid 27 
SL18 was evaluated against clinically relevant fungal/bacterial dual-species biofilms (Candida 28 
albicans, Staphylococcus aureus, Staphylococcus epidermidis) through quantitative and qualitative in 29 
vitro tests.  30 
C. albicans - S. aureus and C. albicans - S. epidermidis cultures were able to produce a dense biofilm 31 
on the surface of the polystyrene plates and on medical-grade silicone discs. All tested BSs 32 
demonstrated an effective inhibitory activity against dual-species biofilms formation in terms of total 33 
biomass, cell metabolic activity, microstructural architecture and cell viability, up to 72h on both these 34 
surfaces. In co-incubation conditions, in which BSs were tested in free soluble form, rhamnolipid 35 
R89BS (0.05 mg/ml) was the most effective among the tested biosurfactants against the formation of 36 
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both dual-species biofilms, reducing on average 94% and 95% of biofilm biomass and metabolic 37 
activity at 72h of incubation, respectively. Similarly, rhamnolipid R89BS silicone surface coating 38 
proved to be the most effective in inhibiting the formation of both dual-species biofilms, with average 39 
reductions of 93% and 90%, respectively. Scanning Electron Microscopy observations showed areas 40 
of treated surfaces that were free of microbial cells or in which thinner and less structured biofilms 41 
were present, compared to controls.  42 
The obtained results endorse the idea that coating of implant surfaces with BSs may be a promising 43 
strategy for the prevention of C. albicans -Staphylococcus spp. colonization on medical devices, and 44 
can potentially contribute to the reduction of the high economic efforts undertaken by healthcare 45 
systems for the treatment of these complex fungal-bacterial infections.  46 
Introduction 47 
Biofilms are complex biological structures, composed of sessile multicellular communities 48 
encapsulated in a hydrated matrix of polysaccharides and proteins, in which microorganisms become 49 
more resistant to drug therapy and host immune response (Chen and Wen, 2011; Pompilio and Di 50 
Bonaventura, 2018). Microbial cells forming biofilms also communicate through the quorum sensing 51 
(QS) system, which is responsible of regulating genes expression, production of proteases and other 52 
signals that enable high-density bacterial cluster to flourish (Buch et al., 2019; Irorere et al., 2019).  53 
Biofilms give rise to chronic infections both in tissues (e.g. lung infection in cystic fibrosis, chronic 54 
wound infections) and on the surface of implantable medical devices (e.g. orthopedic prostheses, 55 
endotracheal tubes, intravenous and urinary catheters, heart valves), which are characterized by the 56 
development of persistent and progressive diseases mainly due to the inflammatory response 57 
surrounding these biofilms (Clinton and Carter, 2015; Percival et al., 2015; Teo et al., 2016; Omar et 58 
al., 2017; Song et al., 2018). This makes many biofilm infections difficult to diagnose or to adequately 59 
treat.  60 
Although most tissue and medical device-associated infections are caused by a single pathogen, an 61 
increasing number of polymicrobial infections has been reported in the clinical practice (Mihai et al., 62 
2015; Rodrigues et al., 2019). The involved microorganisms are believed to coexist and realize 63 
synergistic interactions within the biofilm environment resulting in enhanced pathogenicity, virulence 64 
and resistance to antimicrobials, thus leading to more aggressive forms of infections (Marculescu and 65 
Cantey, 2008; Burmølle et al., 2014). An emerging finding in polymicrobial biofilm research is the 66 
presence of both eukaryotic and prokaryotic pathogens (Brogden et al., 2005). The coexistence of 67 
Candida albicans and Staphylococcus species, in particular, have been frequently associated with 68 
extremely complicated infections and high mortality rates (Tsui et al., 2016). Biofilm-associated 69 
diseases related to C. albicans and Staphylococcus species, including wound infections, periodontitis, 70 
denture stomatitis and medical devices related infections involving catheters and orthopedic implants 71 
have all been described before (Adam et al., 2002; Gupta et al., 2005; Valenza et al., 2008; Cuesta et 72 
al., 2010; Harriott and Noverr, 2011). These polymicrobial infections are difficult to diagnose and are 73 
mostly untreatable with the conventional antibiotic treatment strategies and commonly requires 74 
complex multi-drug therapy and in the vast majority of cases, the removal of infected medical devices 75 
(Harriott and Noverr, 2009; Pammi et al., 2013; Carolus et al., 2019).  76 
This worldwide public health problem requires the development of innovative approaches able to 77 
efficiently tackle infections associated with these bacteria, fungi and their biofilms. For this reason, 78 
several surface-coating strategies have been proposed to safeguard medical devices from microbial 79 
adhesion and colonization (John et al., 2007; Zilberman and Elsner, 2008; Ramasamy and Lee, 2016; 80 
Francolini et al., 2017; Khatoon et al., 2018; Wang and Tang, 2018; Ghensi et al., 2019). Unfortunately, 81 
surface-treated biomaterials showed, in some cases, limited efficacy over time as well as an inherent 82 
risk of cytotoxicity towards cell tissues (Francolini and Donelli, 2010). Therefore, the application of 83 
                                                                      Biosurfactants Against Polymicrobial Biofilms 
 
3 
natural molecules for the creation of new safe and effective biocompatible antibacterial and/or anti-84 
adhesive biomaterial coatings or pharmaceutical products to prevent and treat both single-species and 85 
polymicrobial biofilm infections are urgently required (Vasilev et al., 2011).  86 
Focusing on this goal, biosurfactants (BSs) have been suggested as a new group of antimicrobial/anti-87 
biofilm biocompatible compounds useful in a wide range of pharmaceutical and biomedical 88 
applications (Diaz De Rienzo et al., 2014; Lydon et al., 2017; Elshikh et al., 2017; Juma et al., 2020). 89 
BSs are amphiphilic molecules, produced by a wide group of microorganisms, which partition at and 90 
alter the physical-chemical conditions of the interfaces and are characterized by interesting biological 91 
activities like antimicrobial, anti-adhesive and anti-biofilm properties (Banat et al., 2014; Simms et al., 92 
2020). Biosurfactants ability to destabilize the integrity and permeability of cell membranes and to 93 
modify surface properties of biomaterials, affecting microbial vitality and adhesion, limiting biofilm 94 
formation or reducing the structural integrity of existing biofilms have been reported (Fracchia et al., 95 
2015; Satpute et al., 2016; Fracchia et al., 2019).  96 
Towards this goal, during the past few years, we have demonstrated the ability of lipopeptides, 97 
rhamnolipids and sophorolipids BSs, alone or in combination with antimicrobials and quorum-sensing 98 
molecules to inhibit microbial adhesion and biofilm formation of mono-species biofilms of fungal or 99 
bacterial pathogens on biomedical materials such as silicone (Ceresa et al., 2016, 2017, 2018, 2019a 100 
and 2020). The activity of BSs against biofilm formation on model surfaces such as polystyrene, glass, 101 
silicone and polydimethylsiloxane has also been described in other works (Sharma and Saharan, 2016; 102 
Aleksic et al., 2017; Satpute et al., 2018; Janek et al., 2018). Conversely, to our knowledge, no studies 103 
have been conducted yet concerning the use of BSs against these clinically relevant fungal-bacterial 104 
polymicrobial biofilms. 105 
In this perspective, the present study aimed at testing the efficacy of three different BSs (lipopeptide 106 
AC7BS, rhamnolipid R89BS and sophorolipid SL18) as anti-adhesive and anti-biofilm agents against 107 
the formation of clinically relevant multi-species biofilms composed by fungal and bacterial species 108 
(C. albicans - S. aureus, C. albicans - S. epidermidis) employing a multidisciplinary and multifaceted 109 
approach. 110 
Materials and Methods 111 
Study design 112 
The study was organized in six experimental phases: 1) definition of the dual-species biofilm model 113 
with quantification of biomass production and metabolic activity on polystyrene and silicone elastomer 114 
and comparison with the corresponding single species counterpart; 2) identification of the non-115 
cytotoxic BSs concentrations with a significant inhibitory activity against single species biofilm 116 
formation; 3) evaluation of the anti-biofilm and antimicrobial activity of BSs at the non-cytotoxic 117 
concentrations against polymicrobial cultures, in co-incubation; 4) evaluation of the anti-biofilm and 118 
antimicrobial activity of silicone discs coated with BSs against polymicrobial cultures; 5) assessment 119 
of cells surface hydrophobicity and membrane permeability changes induced by BSs in free soluble 120 
form; 6) observation of the dual-species biofilm micro-structure on BSs-coated silicone discs; 7) 121 
preliminary assessment of BSs-coated silicone discs biocompatibility. 122 
Strains 123 
The rhamnolipid-producer strain Pseudomonas aeruginosa 89, a clinical isolate from a patient with 124 
cystic fibrosis, was cultured from frozen stocks onto Tryptic Soy Agar (TSA, Scharlab, Barcelona, ES) 125 
at 37°C for 18-20h. The lipopeptide-producer strain Bacillus subtilis AC7, from the inside of stems of 126 
Robinia pseudoacacia, was cultured from frozen stocks onto Luria Bertani agar (LBA, Sigma-Aldrich, 127 
St. Louis, USA) at 28°C for 18-20h. The sophorolipid-producer strain Candida bombicola ATCC 128 
                                                                      Biosurfactants Against Polymicrobial Biofilms  
 
4 
This is a provisional file, not the final typeset article 
22214, obtained from the American Type Culture Collection (ATCC - Manassas, VA, USA), was 129 
cultured from frozen stocks onto Sabouraud dextrose agar (SDA, Scharlab, Barcelona, ES) at 25°C for 130 
18-20h. All the biofilm-producer strains used in this study were obtained from the American Type 131 
Culture Collection (ATCC - Manassas, VA, USA). Candida albicans ATCC 10231, Staphylococcus 132 
aureus ATCC 25923, S. aureus ATCC 6538 and S. epidermidis ATCC 35984 were cultured from 133 
frozen stocks onto SDA and TSA plates, respectively and incubated overnight at 37°C. 134 
Biosurfactants production and extraction 135 
Lipopeptide AC7BS and rhamnolipid R89BS were produced and extracted as described by Ceresa et 136 
al. (2018 and 2019a). Briefly, a loop of B. subtilis AC7 from a LBA overnight culture was grown in 137 
20 ml of LB broth at 28°C for 4h at 140 rpm. Afterwards, 2 ml of this culture were used to inoculate 138 
500 ml of LB broth and were incubated at 28°C for 24h at 140 rpm. A loop of P. aeruginosa 89 from 139 
a TSA overnight culture was grown in 40 ml of Nutrient Broth II (Sifin Diagnostics GmbH, Berlin, 140 
DE) for 4h at 37°C at 140 rpm. Afterward, 8 ml of this culture was added to 400 ml of Siegmund–141 
Wagner medium and incubated at 37°C for five days at 120 rpm. Cell-free supernatants were acidified 142 
to pH 2.2 with 6 M HCl (AC7BS) or 6 M H2SO4 (R89BS) and stored overnight at 4°C. Lipopeptide 143 
AC7BS and rhamnolipid R89BS were extracted three times with 167 ml ethyl acetate:methanol (4:1) 144 
or 134 ml ethyl acetate (Sigma-Aldrich, St. Louis, USA), respectively. Organic phases were 145 
anhydrified, filtrated and vacuum-dried. BSs were recovered by dissolution in acetone (Sigma-Aldrich, 146 
St. Louis, USA) and collected in glass tubes. Acetone was, then, evaporated and BSs were weighted. 147 
Sophorolipid SL18 was obtained from a fed batch cultivation of Candida bombicola ATCC 22214, 148 
according to Ceresa et al. (2020). Briefly, the cells (10% v/v) were grown in 2 l of Glucose Yeast Urea 149 
(GYU) medium (100 g/l glucose (Sigma-Aldrich, St. Louis, USA), 10 g/l yeast extract (Sigma-Aldrich, 150 
St. Louis, USA), and 1 g/l urea (Sigma-Aldrich, St. Louis, USA)). Oleic acid (99%, Sigma-Aldrich, 151 
St. Louis, USA) was supplemented as a feeding source at a concentration of 20% to generate lactonic 152 
congeners. Fermentation was performed for 8 days at 200 rpm and 30°C. Sophorolipid SL18 were, 153 
then, extracted twice with ethyl acetate (1:1 extract ratio) (Sigma-Aldrich, St. Louis, USA) and partially 154 
purified by three washings with hexane (Sigma-Aldrich, St. Louis, USA) to remove residual fatty acids. 155 
At the end of each extraction process, the composition of the three BSs was confirmed by ESI/MS 156 
analysis as previously described (Ceresa et al., 2016; Ceresa et al., 2019a; Ceresa et al., 2020). All the 157 
following biological tests and microscopy analyses were performed using the same batch of production 158 
for each BS. BSs were dissolved in Phosphate Buffer Solution pH 7.4 (PBS) at the different 159 
concentrations of use. The solutions were filtered through a 0.2 m filter and stored at room 160 
temperature. 161 
Silicone cleaning and sterilization 162 
Silicone-elastomeric discs (SEDs - 0.8 cm in diameter and 1.5 mm in thickness), were cut from 163 
medical-grade silicone sheets (TECNOEXTR s.r.l, Palazzolo sull’Oglio, IT) and prepared as described 164 
in Ceresa et al. (2015). Briefly, discs were cleaned with a 1.4% (v/v) RBSTM 50 solution (Sigma-165 
Aldrich, St. Louis, USA), sonicated for 5 min at 60 kHz and rinsed twice in Milli-Q water. Silicone 166 
was, then, dipped in MeOH (99%, Sigma-Aldrich, St. Louis, USA), sonicated and rinsed as previously 167 
described. Afterwards, SEDs were autoclaved, dried, and moved aseptically into 48-well plates. 168 
Anti-biofilm assays  169 
Mono- and dual-species biofilm formation: fungal and bacterial cells were suspended in Roswell Park 170 
Memorial Institute (RPMI) 1640 (Sigma-Aldrich, St. Louis, USA) buffered with MOPS (Sigma-171 
Aldrich, St. Louis, USA) and supplemented with 2% Glucose (Biolife, Monza, IT), pH 7.0 (RPMI 172 
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+2%G). Cell density was adjusted up to 106 and 107 Colony Forming Unit (CFU)/ml for C. albicans 173 
and Staphylococcus spp. respectively. Polystyrene was used as a substrate for the growth of biofilms 174 
in co-incubation assays and silicone was used for the growth of biofilms in the coating assays. Surfaces 175 
were inoculated with 0.5 ml of the suspension and incubated at 37°C in static conditions up to 72h; 176 
growth medium was removed and replaced with fresh RPMI +2%G every 24h. Blank polystyrene and 177 
silicone control surfaces (without biofilm) were also included in the experimental setting. The ability 178 
of microbial strains to form polymicrobial biofilms, compared to the mono-species ones, was evaluated 179 
by the determination of biofilm biomass and metabolic activity of sessile cells as described below. All 180 
experiments were carried out in quadruplicate and repeated two times. 181 
Co-incubation conditions (BSs in free soluble form in polystyrene plates): in order to determine the 182 
minimum non-cytotoxic concentration of BSs (Ceresa et al., 2018 and 2019) able to inhibit single-183 
species biofilm formation on polystyrene by at least 80%, increasing concentrations of lipopeptide 184 
AC7BS (0.125-0.5 mg/ml) and rhamnolipid R89BS (0.0125-0.05 mg/ml) were tested until the 185 
concentration of interest was reached. The wells were filled with 50 μl of 10× BSs solutions (treated 186 
samples) or with an equal volume of PBS (control samples) and 0.5 ml of single-species suspensions 187 
of C. albicans (106 CFU/ml) and Staphylococcus spp. (107 CFU/ml) in RPMI +2%G. The 48-well 188 
plates were incubated for 24h at 37°C. The effect was evaluated in terms of biofilm biomass reduction 189 
as described below. All experiments were carried out in quadruplicate and repeated twice. 190 
Subsequently, the selected concentrations of BSs were tested against dual-species biofilm formation. 191 
The bottom of the wells was covered with 50 μl of the selected 10× BSs solutions (treated samples) or 192 
with an equal volume of PBS (control samples). Then, 0.5 ml of the dual-species suspensions of C. 193 
albicans (106 CFU/ml) and Staphylococcus spp. (107 CFU/ml) in RPMI +2%G were added to each 194 
well. The plates were incubated up to 72h at 37°C. Growth medium was removed and replaced with 195 
fresh RPMI +2%G supplemented with 10× BSs solutions (treated samples) or with an equal volume of 196 
PBS (control samples) every 24h. Blank surfaces (without biofilm) were also included in the 197 
experimental setting. The ability of microbial surfactants to inhibit dual-species biofilm formation in 198 
co-incubation conditions was evaluated by the determination of biofilm biomass and metabolic activity 199 
of sessile and planktonic cells as described below. Experiments were performed in quadruplicate and 200 
repeated twice. 201 
Coating conditions: the treatment of silicone surfaces was carried out in 48 well-plates by immersing 202 
SEDs in BS solutions (rhamnolipid R89BS: 2 mg/ml; lipopeptide AC7BS: 2 mg/ml; sophorolipid 203 
SL18: 8 mg/ml) at 37°C for 24h at 180 rpm. These solutions were chosen as previously optimized in 204 
Ceresa et al. (2016), Ceresa et al. (2019a), Ceresa et al. (2020). Afterwards, discs were moved into new 205 
plates and dried before use. Five hundred microliters of the dual-species suspensions (C. albicans at 206 
the concentration of 106 CFU/ml and Staphylococcus spp. at the concentration of 107 CFU/ml) in RPMI 207 
+2%G were added to each well. SEDs were incubated up to 72h at 37°C. Every 24h, discs were moved 208 
into fresh media. Blank surfaces (without biofilm) were also included. The anti-biofilm activity of BSs 209 
was evaluated at 24, 48 and 72 h by the determination of biofilm biomass, metabolic activity of sessile 210 
and planktonic cells and viable cell counting as described below. Experiments were performed in 211 
quadruplicate and repeated twice. 212 
Biofilm biomass  213 
The determination of the total biomass was carried out by crystal violet staining according to Ceresa 214 
et al. (2019a), with minor changes. Briefly, biofilms were washed twice and stained with 0.5 ml of the 215 
CV solution (0.1%) for 10 min. After the removal of the excess of dye, CV was dissolved with 0.5 ml 216 
of acetic acid (33% in water). Absorbance of the solutions was measured at 570 nm (A570) (Victor3VTM, 217 
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Perkin Elmer, Italy), data were normalized to blank surfaces (background) and percentages of 218 
inhibition were calculated using the following formula: 219 
                                                                               (1 −
Atreat
ACTRL
) × 100                                                         (1) 220 
where: 221 
Atreat; absorbance of treated samples  222 
ACTRL; absorbance of controls. 223 
Biofilm metabolic activity 224 
The determination of biofilm metabolic activity was carried out by means of the colorimetric MTT 225 
assay according to Ceresa et al. (2019a), with minor changes. Briefly, biofilms were washed twice and, 226 
then, dipped in 0.5 ml of MTT working solution (0.075% MTT (Scharlab, Barcelona, ES) solution 227 
supplemented with 0.1% glucose (Biolife, Monza, IT) and 10 μM menadione (Sigma-Aldrich, St. 228 
Louis, USA)). After 30 min of incubation at 37°C in static conditions, MTT solution was removed and 229 
formazan crystals formed by metabolic active cells within biofilms were dissolved with 0.5 ml of the 230 
lysis solution (dimethyl sulfoxide (DMSO)/0.1 M glycine buffer (pH 10.2) solution (7:1)). The A570 of 231 
the solutions was measured, data were normalized to background and percentages of inhibition were 232 
calculated according to formula (1). 233 
Planktonic cells metabolic activity 234 
The metabolic activity of planktonic cells in supernatants was evaluated by the MTT assay according 235 
to Ceresa et al. (2019a), with minor changes. Briefly, growth media and washing solutions, from each 236 
treated and untreated surface, were collected after 24h, 48h and 72h. Microbial cells were harvested by 237 
centrifugation at 17000 rpm for 15 min and incubated in 0.5 ml of the MTT working solution for 30 238 
min. Afterwards, cells were collected by centrifugation at 17000 rpm for 15 min, MTT solution was 239 
removed and formazan crystals were dissolved with 0.5 ml of the lysis solution. The A570 of the 240 
solutions was measured and data were normalized to background. 241 
Quantification of viable sessile cells  242 
The number of microbial cells forming the multi-species biofilms was determined by the spread plate 243 
method as described in Ceresa et al. (2015). Briefly, after two washings, biofilms were detached from 244 
silicone surfaces and broke up by four cycles of sonication (30s) and stirring (30s). The obtained 245 
suspensions were serially diluted in PBS and seeded both on Mannitol Salt Agar (MSA, Scharlab, 246 
Barcelona, ES) plates, selective for staphylococcal species, and on Sabouraud Chloramphenicol Agar 247 
(SCA, Scharlab, Barcelona, ES) plates, selective for fungal species. After 24h at 37°C, the colonies 248 
were counted and the number of C. albicans, S. aureus or S. epidermidis cells within the polymicrobial 249 
biofilm were quantified.  250 
Anti-adhesive assay 251 
SEDs surface coating with the BSs was carried out as described by Papa et al. (2015), with minor 252 
changes. Briefly, a volume of 20 μl of BS solutions (rhamnolipid R89BS: 2 mg/ml; lipopeptide 253 
AC7BS: 2 mg/ml; sophorolipid SL18: 8 mg/ml) or 20 μl of PBS as control, were deposited on the 254 
silicone surfaces. SEDs were then placed under laminar flow to allow complete drying and, 255 
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subsequently, moved into 48 well-plates. The discs were filled with 0.5 ml of the dual-species 256 
suspensions (C. albicans at the concentration of 106 CFU/ml and Staphylococcus spp. at the 257 
concentration of 107 CFU/ml in RPMI +2%G) and incubated at 37°C for 4 h. The quantification of 258 
cells attached on SEDs was carried out using crystal violet staining as reported in “Biofilm biomass” 259 
section. All experiments were carried out in quadruplicate and repeated twice. 260 
Cell surface hydrophobicity and membrane permeability changes by BSs in free soluble form  261 
Cell surface hydrophobicity: bacterial and fungal suspensions were prepared in PBS to obtain an optical 262 
density (OD) at 600 nm respectively of 0.5 and 0.4 and treated with BSs (final concentration R89BS – 263 
0.05 mg/ml, AC7BS – 0.5 mg/ml) at 37°C for 1h at 150 rpm. Untreated suspensions were taken as 264 
control. Cell hydrophobicity was measured by microbial adherence to hexadecane (Scharlab, 265 
Barcelona, ES) according to Rosenberg et al. (1980). Microbial cells were collected by centrifugation 266 
at 4000 rpm for 15 min and resuspended in PUM Buffer, pH 7.1 (22.2 g K2HPO4 • 3H20, 7.26 g 267 
KH2PO4, 1.8 g urea, 0.2 g MgSO4 • 7H20 and distilled water to 1 l). One milliliter of hexadecane was 268 
mixed to 4 ml of cell suspensions in a glass tube at high speed for 2 min and equilibrated for 10 min. 269 
Afterward, the OD of the initial cell suspensions and aqueous phases were measured at 550 nm 270 
(Genova Plus, Jenway, UK) and cell hydrophobicity was calculated using the following formula: 271 
                                                                (1 −
ODaqueous phase
ODinitial cell suspension
) × 100                                                     (2) 272 
Cell membrane permeability: bacterial and fungal suspensions were prepared in PBS to obtain an 273 
optical density (OD) at 600 nm respectively of 0.5 and 0.4 and treated with BSs (final concentration: 274 
R89BS – 0.05 mg/ml, AC7BS – 0.5 mg/ml) at 37°C for 1h at 150 rpm. Untreated suspensions were 275 
taken as control. Cell membrane permeability was evaluated by checking crystal violet enhanced 276 
penetration. Cells were collected by centrifugation at 4000 rpm for 15 min and resuspended in PBS 277 
containing crystal violet (10 g/ml) and incubated at 37°C at 150 rpm for 20 min. Afterwards, cells 278 
were collected by centrifugation at 4000 rpm for 15 min and the absorbance (A) of the solutions was 279 
measured at 590 nm (Genova Plus, Jenway, UK). The percentage of crystal violet uptake was estimated 280 
using the following formula: 281 
                                                                (
Asample
Ainitial crystal violet solution
) × 100                                                  (3) 282 
Experiments were performed in triplicate and repeated three times. 283 
Biofilm architecture 284 
The micromorphology and architecture of multi-species biofilm on SEDs was visualized using the 285 
Scanning Electron Microscope (SEM) Quanta 200F FEG (Fei, Eindhoven, The Netherlands) in high-286 
vacuum mode. Samples were prepared for SEM imaging according to Ceresa et al. (2019a), with minor 287 
changes. Briefly, after two washings, biofilms were fixed in 2.5% glutaraldehyde, washed twice in 288 
distilled water, dehydrated in a graded ethanol series and coated with a 10 nm layer of gold with a 289 
sputter coater (Emitech K500X, Quorum Technologies, Laughton, UK). A set of representative images 290 
at a magnification of 500x, 1000x, 2000x, and 4000× were obtained from untreated (controls) and pre-291 
coated SEDs with rhamnolipid R89BS or sophorolipid SL18 and incubated with either C. albicans - S. 292 
epidermidis or C. albicans - S. aureus at 24h, 48h, and 72h. Secondary electron signal was collected to 293 
investigate structural details of microbial cells and extracellular matrix on the biofilm. The primary 294 
beam energy was set to 5 keV to minimize damage to the organic structures. Possible artefacts due to 295 
                                                                      Biosurfactants Against Polymicrobial Biofilms  
 
8 
This is a provisional file, not the final typeset article 
the sample preparation process were considered according to indications provided by Hrubanova et al. 296 
(2018) and previous experience performed in imaging microbial biofilm formed in-vitro on medical 297 
devices (Tessarolo et al., 2007; Signoretto et al., 2013). 298 
Biocompatibility of BS-coated silicone discs 299 
The in vitro biocompatibility of BSs-coated discs was evaluated in 48-well plates by the MTT assay 300 
(Ceresa et al., 2019b). Spontaneously immortalized human skin keratinocyte - HaCaT cells (104 301 
cells/well) were seeded in Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose (EuroClone, 302 
Milan, IT) supplemented with 4% FBS (EuroClone, Milan, IT), L-glutamine 200 nM (EuroClone, 303 
Italy) and 1% Pen/Strep (EuroClone, Milan, IT) and incubated at 37°C in 5% CO2. After 24h, growth 304 
medium was removed and replaced with the 24h conditioned-surface contacting medium obtained from 305 
static release at 37°C. Negative control consisted in cells treated with 0.5% Triton X, whereas positive 306 
control was represented by cells w/o any treatment. Fifty microliters of the MTT solution (5 mg/ml) 307 
were added into each well. Plates were then incubated for 24h and 72h at 37°C. Formazan crystals 308 
were dissolved with 200 μl of 0.05 M HCl/isopropanol (50:1) and A570 was measured at the two time 309 
points. The percentage of cell viability was estimated using the following formula: 310 
                                                                            (
Asample
ACTRL+
) × 100                                                                 (4) 311 
where: 312 
Asample; absorbance of BSs or CTRL- samples  313 
ACTRL+; absorbance of positive controls. 314 
Experiments were performed in triplicate and repeated twice. 315 
Data analysis and statistics 316 
All analyses and graphics were performed using the statistical program R, 3.6.2. (R Core Team (2019). 317 
R: A language and environment for statistical computing. R Foundation for Statistical Computing, 318 
Vienna, Austria. URL https://www.R-project.org/.). One-way ANOVA was applied to compare mono- 319 
and dual-species biofilms. Two-way ANOVA followed by Tukey post hoc test was used to investigate 320 
the anti-biofilm activity of BSs on dual-species biofilms and the metabolic activity of planktonic cells. 321 
To estimate log10 CFU/disk from colony counts, the R package dupiR was used (Comoglio et al., 2013). 322 
Differences in the percentage composition of dual-species biofilms were investigated by 2-sample t-323 
test for equality of proportions with continuity correction. Two-sample t-test was performed to evaluate 324 
the significance of data in hydrophobicity and membrane permeability assays. One-way ANOVA 325 
followed by Tukey post hoc test was performed to evaluate the significance of data in the 326 
biocompatibility assay in comparison to positive and negative controls. Differences were considered 327 
statistically significant at p<0.05. 328 
Results 329 
Biosurfactants anti-biofilm and antiadhesive activity 330 
Mono- and dual-species biofilms of C. albicans - Staphylococcus spp. were grown on polystyrene 331 
(Figure 1) and on silicone surfaces (Figure 2) up to 72h. Biofilm biomass and biofilm metabolic activity 332 
were quantified at 24h, 48h and 72h. C. albicans - S. aureus biomass and metabolic activity were higher 333 
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than those of the two individual species both on polystyrene and on silicone at all incubation times 334 
(p<0.001). Concerning C. albicans - S. epidermidis, biomass and metabolic activity were always higher 335 
than those observed for the individual species, on both surfaces, up to 48h (p<0.001). On the contrary, 336 
at 72h, biomass and metabolic activity of dual-species biofilms were lower than those observed for S. 337 
epidermidis biofilms, with the exception of metabolic activity on polystyrene (p<0.001).  338 
For the co-incubation assays, AC7BS and R89BS were selected as non-cytotoxic additives at the 339 
concentrations active against biofilm (Ceresa et al., 2018 and 2019). SL-18 was not included because, 340 
when tested in free soluble form, cytotoxicity was previously observed at concentrations that showed 341 
inhibitory activity against C. albicans and S. aureus single species biofilms co-incubation assays 342 
(Ceresa et al., 2020). Increasing concentrations of lipopeptide AC7BS (0.125-0.5 mg/ml) and 343 
rhamnolipid R89BS (0.0125-0.05 mg/ml) were tested and the minimum concentration of BSs that 344 
counteracted single-species biofilms formation on polystyrene by at least 80% (inhibition level 345 
threshold) was identified (Figure 3). In general, the formation of C. albicans and S. aureus biofilms 346 
was reduced in a concentration-dependent manner by the two BSs while the formation of S. epidermidis 347 
biofilm was effectively inhibited (80%) only by rhamnolipid R89BS. In particular, the three mono-348 
species biofilms were inhibited by about 87% by rhamnolipid R89BS at a concentration of 0.05 mg/ml. 349 
Concerning lipopeptide AC7BS, the threshold inhibition level was reached at a concentration of 0.5 350 
mg/ml only for C. albicans and S. aureus biofilms (82%) but not for S. epidermidis, which had a 351 
maximum inhibition of only 27%. For this reason, this BS was excluded from the subsequent anti-352 
biofilm assays against C. albicans - S. epidermidis dual-species biofilms.  353 
The boxplot in Figure 4 shows the effect of rhamnolipid R89BS and lipopeptide AC7BS against C. 354 
albicans - S. aureus and of R89BS against C. albicans - S. epidermidis biofilm formation up to 72h. In 355 
general, as confirmed by two-way ANOVA and Tukey post-hoc test, for each co-culture, biofilm 356 
formation on polystyrene was significantly dependent on BSs treatment (p<0.001) and incubation time 357 
(p<0.001). Regardless of the two strain combinations involved in the dual-species biofilm 358 
development, biofilm biomass (Figure 4A, 4D) and metabolic activity (Figure 4B, 4E) were equally 359 
inhibited by the BSs. The anti-biofilm activity of rhamnolipid R89BS was stable up to 72h, while, for 360 
lipopeptide AC7BS a slight reduction was detected between 24h and 72h. In particular, as observed in 361 
Table 1, rhamnolipid R89BS proved to be the most effective biosurfactant for the inhibition of C. 362 
albicans - S. aureus biofilm growth and an excellent agent for the prevention of C. albicans - S 363 
epidermidis biofilm formation, with mean percentages of reduction of 94% (C. albicans - S. aureus) 364 
and 95% (C. albicans - S epidermidis), after 72h co-incubation. In addition, to define whether part of 365 
the observed effect was the result of an antimicrobial activity of the BSs, the metabolic activity of 366 
planktonic cells in the supernatants was assessed (Figure 4C, 4F). The absorbance values of the cell 367 
supernatants co-incubated with BSs were significantly higher in comparison to the controls (p<0.001) 368 
suggesting that, in the treated wells, cells existed in a planktonic state rather than by forming a biofilm. 369 
However, in the case of C. albicans - S. aureus co-cultures, the lower absorbance values observed in 370 
the rhamnolipid R89BS-treated wells compared to those of the lipopeptide AC7BS-treated wells 371 
(p<0.001), suggested an antimicrobial activity of the rhamnolipid (Figure 4C). 372 
The results of BSs pre-coating on SEDs further confirmed the inhibitory activity of these natural 373 
microbial molecules against the formation of C. albicans - S. aureus (rhamnolipid R89BS, lipopeptide 374 
AC7BS, sophorolipid SL18) and C. albicans - S epidermidis (rhamnolipid R89BS, sophorolipid SL18) 375 
mixed biofilms (Figure 5). As previously observed in co-incubation conditions, for each co-culture, 376 
the development of biofilms on silicone surfaces was significantly dependent on BSs treatment 377 
(p<0.001) and incubation time (p<0.001). Biofilm biomass (Figure 5A, 5D) and metabolic activity 378 
(Figure 5B, 5E) were equally inhibited on all BSs-coated discs (SEDs). Concerning the dual-species 379 
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biofilms of C. albicans - S. aureus, the anti-biofilm activity of rhamnolipid R89BS- and sophorolipid 380 
SL18-coated SEDs was stable up to 72h, while, a slight reduction of the efficacy of lipopeptide 381 
AC7BS-coated SEDs was observed during this time. The anti-biofilm activity of rhamnolipid R89BS 382 
coating was stable also for C. albicans - S epidermidis mixed biofilms, while that of sophorolipid SL18-383 
coated SEDs slightly decreased over time. In general, starting from 48h of incubation, the surface 384 
treatment of silicone with rhamnolipid R89BS proved to be the most effective in counteracting the 385 
growth of both polymicrobial biofilms. In particular, after 72h, average inhibitions of 93% and 90% 386 
against C. albicans - S. aureus and C. albicans - S. epidermidis biofilms were found, respectively. 387 
Table 2 shows the percentages of biomass and metabolic activity inhibition at the different time-points. 388 
To exclude that the observed activity was due to an antimicrobial action of the BSs, the metabolic 389 
activity of the planktonic cells in the wells was evaluated (Figure 5C, 5F). As observed in co-incubation 390 
conditions, the absorbance values of the supernatants of the BSs-coated silicone discs were 391 
significantly higher than those obtained for the corresponding controls (p<0.001). Conversely, no 392 
significant variations were found between the absorbance values of planktonic cells recorded for the 393 
different BSs treatments (p>0.05).   394 
In addition, to evaluate whether the tested BSs exhibited their anti-biofilm action in equal proportions 395 
on the single species forming the polymicrobial biofilms on the silicone surfaces, the number of cells 396 
of C. albicans, S. aureus and S. epidermidis were determined on selective media for both control and 397 
coated discs (supplementary Table 1 and Table 2) and the percentage composition were calculated 398 
(Table 3 and Table 4). In general, at all incubation times, biofilms on the control discs mainly consisted 399 
of bacterial cells (98.6-99.8%) and only for a small percentage of the yeast cells (0.2-1.4%). In 400 
particular, the yeast cells were present in a major proportion in C. albicans - S. aureus biofilms (Table 401 
3) than in C. albicans - S. epidermidis (Table 4). Interestingly, at 24h, the presence of BSs on the 402 
silicone surface was associated with a significant increase in the yeast species percentage compared to 403 
that observed on the controls (p<0.001). However, this value decreased over time and returned to levels 404 
similar to those observed for the controls. 405 
 406 
Finally, to assess the activity of BSs coating on SEDs on the early phases of biofilm formation 407 
(adhesion phase), the amount of C. albicans - S. aureus and C. albicans - S. epidermidis adherent cells 408 
was evaluated after 4 h incubation by means of the CV method (Figure 6). Similarly, to biofilm 409 
formation, microbial cells adhesion to silicone surfaces was also significantly dependent on BSs 410 
treatment (p<0.001). Concerning C. albicans - S. aureus, the highest anti-adhesive activity was 411 
observed for rhamnolipid R89BS (71%), followed by sophorolipid SL18 (64%) and lipopeptide 412 
AC7BS (51%). As to C. albicans - S. epidermidis, rhamnolipid R89BS coating proved to be the most 413 
effective with an inhibition of adhesion of 62% while sophorolipid SL18 showed a 54% inhibition.  414 
Cell surface hydrophobicity and membrane permeability changes by BSs in free soluble form 415 
In order to evaluate the possible effect of BSs on the tested opportunistic pathogens in co-incubation 416 
conditions, cell surface hydrophobicity and membrane permeability were assessed. As shown in Figure 417 
7A, after 1h incubation with R89BS and AC7BS, cell surface hydrophobicity (CSH) and membrane 418 
permeability of C. albicans, S. aureus and S. epidermidis were different from the untreated controls. 419 
BSs treatment induced a significant modification of CSH for all the tested strains (p<0.05). In 420 
particular, it resulted in a decrease of CSH both for bacterial and fungal cells. Bacterial cells CSH 421 
decreased from 99% (untreated control samples) to values ranging from 71% to 38% (BSs treated 422 
samples). For fungal cells, CSH in comparison was reduced from 44% (control samples) to values 423 
ranging from 31% to 37% (BSs treated samples). The changes of CSH induced by BSs were related to 424 
the microbial strain: in particular, S. aureus was the most susceptible to cell hydrophobicity changes, 425 
followed by S. epidermidis and C. albicans. The treatment with BSs also altered cell membrane 426 
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permeability for all the tested strains (p<0.05) (Figure 7B). In particular, BSs induced an increase in 427 
crystal violet uptake by bacterial cells from 46% (average untreated control samples) to values ranging 428 
from 54% to 74% and a slight increase in the case of fungal cells from 53% (untreated control samples) 429 
to values ranging from 56% to 59%. Again, the changes of membrane permeability induced by BSs 430 
were related to the microbial strain: in particular, S. aureus and S. epidermidis were more susceptible 431 
to BSs than C. albicans.  432 
Scanning Electron Microscopy of multi-species biofilms on SEDs 433 
SEM images presenting the features of the biofilm formed on untreated (controls) and pre-coated SEDs 434 
with rhamnolipid R89BS and sophorolipid SL18 at the longest incubation time is presented in Figure 435 
8. The SEM investigation showed the presence of both fungal hyphae and coccoid bacteria adhering to 436 
the surface of all samples. In general, there was a more pronounced spatial correlation between S. 437 
aureus and C. albicans (Figure 8A, 8C, 8E) than between S. epidermidis and C. albicans (Figure 8B, 438 
8D, 8F), irrespective of the surface treatment. More specifically, S. aureus was prevalently found in 439 
close contact with fungal hyphae, almost completely covering the Candida mycelium at 72h in control 440 
SEDs (Figure 8A), while S. epidermidis never realized a full coating of the C. albicans structures 441 
(Figure 8B) and was more prone to adhere directly to the SEDs surface (Figure 8D).  442 
In agreement with the results obtained from quantitative tests of biofilm biomass performed on 443 
corresponding samples, untreated controls showed a well-structured dual-species biofilm at each time-444 
points, having a more three-dimensional arrangement and a thicker appearance at longer incubation 445 
times (Figure 8A, 8B). A similar increasing trend in the number of cells at the surface was observed 446 
also for rhamnolipid R89BS and sophorolipid SL18 pre-coated SEDs. However, the number of 447 
microbial cells at the treated surface was drastically reduced in respect to controls and the large 448 
majority of the sample surface was free of cells or presented small clusters with few three-dimensional 449 
microbial aggregates at 24h and 48h (Supplementary Figure S1, S2). This was also the case for S. 450 
aureus and C. albicans dual-species biofilm at 72h (Figure 8C, 8E), but not for S. epidermidis and C. 451 
albicans dual-species biofilm where only a minor portion of the treated surface was free of cells (Figure 452 
8D) or mainly fully covered (Figure 8F). At 72h, some differences in C. albicans - S. epidermidis 453 
biofilms were also noted between rhamnolipid R89BS and sophorolipid SL18 pre-coated discs, with 454 
the latter presenting areas showing a mature biofilm (Figure 8F), although less structured and thick 455 
than the controls (Figure 8B). Rhamnolipid R89BS pre-coated SEDs showed only minor portions of 456 
the disc surface still free of microorganisms (Figure 8D). 457 
Cytotoxicity of BSs-coated silicone discs 458 
No cytotoxic effect was detected on spontaneously immortalized human skin keratinocyte when 459 
exposed for 24h to the BSs-coated SEDs eluates obtained from static release conditions. In fact, at this 460 
time-point, the viability of HaCat cells were comparable to positive controls (p>0.05), independently 461 
to the type of BS involved in the coating procedure (Supplementary Figure S3A). After 72h of cells 462 
exposure to the eluates, cell viability slightly decreased to values ranging from 92% for SL18 to 78% 463 
for R89BS (Supplementary Figure S3B) but was always above the limit (70%) according to the UNE-464 
EN-ISO 10993-5 standard (Xian, 2010; Rodríguez-López et al., 2020).  465 
Discussion 466 
Microbial colonization and biofilm formation on medical devices represent one of the major challenges 467 
in infection control (Persival et al., 2015; Wang et al., 2017; Khatoon et al., 2018). Biofilms protect 468 
microbial cells from antimicrobials and the immune system of hosts and, in most cases, this may lead 469 
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to the dysfunction of the devices and eventual removal (Persival et al., 2015; Sharma et al., 2019; 470 
Khatoon et al., 2018). 471 
Nowadays, Candida albicans is considered as the prevailing fungal pathogen responsible for severe 472 
hospital-acquired infections and has also been reported to form polymicrobial biofilms in coexistence 473 
with bacterial species such as Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas 474 
aeruginosa and Streptococcus spp. (Liu et al., 2019). These microbial pathogens are well known for 475 
their ability to form persistent biofilms on biotic and abiotic surfaces such as tissues, organs and 476 
medical-devices, including dentures, voice prostheses, implants, endotracheal tubes, feeding tubes, and 477 
most frequently, catheters (Liu et al., 2019; Carolus et al., 2019) 478 
The existence of these multi-species communities makes the challenge against biofilms even more 479 
complex because it does not only require effective antimicrobials against all pathogenic 480 
microorganisms present in the microbial community, but limits the effectiveness of to date-developed 481 
species-specific biofilm targeting strategies (Koo et al., 2017). Based on these considerations, 482 
numerous researchers have aimed their studies at identifying new and effective approaches to 483 
counteract polymicrobial biofilms, both in terms of inhibition of microbial adhesion and disruption of 484 
mature biofilms (Villa and Cappitelli, 2013). Among these, the use of new antimicrobial peptides has 485 
been suggested as a promising treatment against fungal/bacterial polymicrobial biofilms (Qu et al., 486 
2016; de Alteriis et al., 2018; Gupta et al., 2019). Through a different mechanism of action, these 487 
molecules can cause microbial death, inhibit bacterial growth and compromise biofilm formation and 488 
architecture. Weiland-Bräuer et al. (2019) identified, in the metagenome-derived bacterial quorum 489 
quenching (QQ), proteins QQ-5 and QQ-7 as an effective strategy to prevent C. albicans and S. 490 
epidermidis biofilm formation, by inhibiting C. albicans yeast-to-hyphae transition and inducing the 491 
expression of the icaR gene, thus repressing the synthesis of polysaccharide intercellular adhesion 492 
(PIA). 493 
A further strategy currently proposed to treat C. albicans - S. aureus infections is based on combined 494 
therapies of existing antimicrobials or treatments with natural molecules, such as plant extracts or 495 
essential oils, alone or in combination with antibiotics or antifungals (Budzynska et al., 2017; Scafarro 496 
et al., 2018; Tan et al., 2019).  497 
In this scenario, BSs effectively appear to be promising new candidates for biofilm inhibition in the 498 
biomedical field due to their interesting antimicrobial, anti-adhesive properties (Banat et al., 2010; 499 
Rodrigues et al., 2010; Fracchia et al., 2019; Naughton et al., 2019). These molecules, in fact, are able 500 
to counteract effectively biofilms by decreasing microbial cells viability and by reducing microbial 501 
adhesion (Satpute et al., 2016; Fracchia et al., 2019; Paraszkiewicz et al., 2019; Naughton et al., 2019). 502 
When BSs bind to cell wall surface, they may form a film that changes the wettability and the surface 503 
energy of the cell leading to severe changes in its hydrophobicity and increasing its permeability by 504 
the release of LPS and the formation of transmembrane pores. When applied as coating-agents, BSs 505 
interfere with microbial adhesion and limit biofilm formation altering the chemical and physical 506 
properties of the surfaces (e.g. reduction of roughness and hydrophobicity or increase of wettability) 507 
on which biofilms develop (Rodrigues et al., 2006; Quinn et al., 2013; Satpute et al., 2019).  508 
In this study, we demonstrated the ability of different BSs to inhibit the formation of fungal and 509 
bacterial dual-species biofilms for up to three days in both co-incubation and pre-coating assays. One 510 
lipopeptide (AC7BS) and two glycolipids (R89BS and SL18) were tested. As observed by the positive 511 
ESI–MS analysis, AC7BS is composed of surfactin (98%) and fengycin (2%) homologues (Ceresa et 512 
al., 2016). Surfactin family members are represented by C13, C14 and C15 homologues whereas 513 
fengycin family members are represented by two main fengycin isoforms corresponding to C17 514 
fengycin A and C17 fengycin B. The negative electrospray ionization (ESI) MS analysis of R89BS 515 
extract showed the presence of mono- (75%) and di- (25%) rhamnolipid homologues. Mono-516 
rhamnolipid family members are represented by C10–C10, C8–C10, and C10–C12, homologues 517 
whereas di-rhamnolipid family members by C10–C8, C10–C10, and C10–C12 homologues (Ceresa et 518 
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al., 2019a). Sophorolipid SL18 is a mixture of lactonic congeners (Ceresa et al., 2020). The fungal 519 
strain C. albicans and the bacterial strains S. aureus and S. epidermidis were selected as they represent 520 
a major cause of medical device associated infections due to their ability to adhere to biomaterials and 521 
form antimicrobial-resistant multispecies biofilms (Arciola et al., 2005; Von Eiff et al., 2006; Sardi et 522 
al., 2013; Carolus et al., 2019). 523 
The experiments reported in this study were carried out using culture media and growth conditions that 524 
support the reproducible development of well-structured dual-species biofilms, as demonstrated by the 525 
high values of biofilm biomass and cell metabolic activity detected for the controls and by SEM images 526 
of control biofilms. BSs were tested in solution or coated on silicone surfaces by physical absorption. 527 
Dual-species cultures were evaluated by the quantification of different parameters: biomass, metabolic 528 
activity, and number of viable cells. The microstructure of dual-species biofilms on treated and 529 
untreated silicone was also characterized by SEM analysis.   530 
The lipopeptide AC7BS and the rhamnolipid R89B, tested in free soluble form in co-incubation 531 
conditions, showed a significant inhibitory activity against the formation of dual-species biofilms of 532 
C. albicans and Staphylococcus spp. determining high levels of reduction, both in terms of total 533 
biomass and metabolic activity with inhibitions ranging from 84% to 96% at 72h. These findings 534 
suggest a potential applicability of these BSs as components of pharmaceutical formulations, such as 535 
injectable scaffolds or hydrogels enriched with antimicrobial or anti-biofilm agents useful in wound 536 
healing. Similar conclusions were also reached by for better wound healing when microbial glycolipid 537 
biosurfactant-containing ointment was used as a transdermal substitute treatment process (Gupta et al., 538 
2017).  539 
Coating of silicone surfaces with lipopeptide AC7BS, rhamnolipid R89BS and sophorolipid SL18 was 540 
as much beneficial, further confirming the inhibitory activity of these natural molecules against the 541 
formation of both dual-species biofilms, with percentages of inhibition at 72h ranging from 77% to 542 
93%. R89BS in particular was found to be the most effective biosurfactant in inhibiting both dual-543 
species biofilms on both surfaces.  544 
Both rhamnolipids and sophorolipids have also shown to be active against other multi-species cultures 545 
(Diaz De Rienzo et al., 2016). They observed using the BioFlux flow through conditions, that a 546 
combination of caprylic acid (0.01% v/v) and rhamnolipids (0.04% v/v) caused the disruption of single 547 
and mixed biofilms for P. aeruginosa and S. aureus. Biofilms were also efficiently dislodged by the 548 
combination of rhamnolipids (0.04% v/v) with sophorolipids (0.01% v/v). Interestingly, these authors 549 
observed that biofilm disruption of S. aureus and mixed cultures was caused by the anti-biofilm 550 
properties of BSs without affecting cell viability whereas for the P. aeruginosa biofilms, a high rate of 551 
killed cells was observed.  552 
According to the studies conducted so far, in co-incubation conditions, the anti-biofilm activity of the 553 
tested BSs seemed to be related to a reduction of cell surface hydrophobicity and thus to a change in 554 
cells ability to adhere to the silicone surface (Elshikh et al., 2016) For rhamnolipid R89BS, the effect 555 
was also partly associated to its antibacterial activity on staphylococcal cells, as demonstrated in a 556 
previous work (Ceresa et al., 2019a) and confirmed in this study by the observed decrease of the 557 
planktonic cells metabolic activity and the increase in membrane permeability. On the contrary, an 558 
antifungal effect on C. albicans was not observed at the tested concentrations, indicating that the 559 
antimicrobial activity of the rhamnolipid is also microorganism dependent as observed by Diaz De 560 
Rienzo et al. (2016). Lipopeptide AC7BS was in general less efficient in counteracting S. epidermidis 561 
biofilm formation as suggested by the fact that the inhibition level threshold of 80% was not reached 562 
when tested in co-incubation conditions against single species biofilm. In addition, cell surface 563 
hydrophobicity assays indicated that S. epidermidis was less susceptible to cell hydrophobicity changes 564 
induced by AC7BS compared to S. aureus. Moreover, S. epidermidis cell permeability was less 565 
affected in the presence of AC7BS in comparison to rhamnolipid R89BS. It may be hypothesized that 566 
the ability of this strain to produce a high amount of slime (Arciola et al. 2001; Williams and Bloebaum, 567 
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2010) might have interfered with the activity of AC7BS in the co-incubation conditions. Furthermore, 568 
AC7BS did not show any antimicrobial activity against S. epidermidis (Ceresa, et al. Biosurfactant-569 
based coatings inhibit fungal and bacterial biofilm on medical-grade silicone. TERMIS 2017. Davos, 570 
Switzerland, eCM Meeting Abstracts 2017, Collection 2; TERMIS EU (P821)) whereas, as far as 571 
R89BS is concerned, a MIC99 was detected at 120 µg/mL (Ceresa et. al., 2019a) indicating a higher 572 
efficacy of the rhamnolipid against this strain compared to the lipopeptide.  573 
When applied on silicone surfaces as coating agents, BSs effects were mostly related to their anti-574 
adhesive properties. Surface physicochemical characterization of BSs-coated discs showed an 575 
increased level of wettability, i.e. a reduction of hydrophobicity (static contact angle for AC7BS-coated 576 
SEDs: 94.4°  10.0°; dynamic contact angle for R89BS-coated SEDs: 84.4° ± 2.2° (advancing) and 577 
72.2° ± 2.5° (receding)), in comparison to control discs (112° ± 5°) (Ceresa et al. 2016, 2019a). In 578 
addition, concerning R89BS, the anti-biofilm effect in the pre-coating conditions was not due to an 579 
antimicrobial activity, as indicated by the fact that planktonic cells metabolic activity was similar to 580 
that observed in the presence of the other BSs, thus suggesting that the amount of R89 deposited on 581 
the silicone surface was largely below the biocidal concentration for staphylococci. 582 
The impact of the BSs pre-coating in the formation of dual-species biofilm on the surface of medical 583 
grade silicon was also observed by SEM inspection. R89BS and SL18 almost completely prevented 584 
the attachment of the dual-species biofilms up to 48h, and a clear reduction in the amount of biofilm 585 
with respect to controls was still evident at 72h of incubation. 586 
Differences in the cell arrangements and, more specifically, in the relative spatial distribution of cocci 587 
and yeasts was noted between C albicans - S aureus and C. albicans - S. epidermidis, whereas no 588 
influence on the inter-species spatial association was observed by comparing BS-coated and untreated 589 
silicone surfaces. A stronger association between the fungal and bacterial cells was observed in the C 590 
albicans - S aureus biofilm. As previously reported by Harriot and Noverr (2009), S. aureus mainly 591 
formed microcolonies on the surface of the biofilm, with C. albicans serving as the underlying 592 
scaffolding. Compared to S. epidermidis, S. aureus was not as effective in forming biofilms on abiotic 593 
surfaces, requiring precoating and supplementation of nutrients (Cassat et al., 2007). C. albicans was 594 
shown to play an essential role in producing extracellular matrix that facilitates S. aureus adhesion and 595 
sessile microcolonies formation (Harriot and Noverr, 2009). The C. albicans - S. epidermidis biofilm 596 
was characterized by a more open hyphal network and the association of S. epidermidis cells with the 597 
fungal structures was less marked. S. epidermidis cells were found beneath and above the yeast cells 598 
and hyphal layers and the Staphylococci cells were clearly adherent to both morphological forms of 599 
the fungus as previously reported by other authors (Adam et al., 2002). Anyway, the adhesion and 600 
microcolonies formations of S. epidermidis on the surface of the silicone samples were frequently noted 601 
also in absence of fungal cells, possibly due to their higher ability to produce extracellular matrix.  602 
Apparent discrepancies between results from the biofilm biomass evaluation (Table 2) and the 603 
corresponding SEM images (e.g. Fig. 8C and Fig. 8D differ significantly despite similar reduction 604 
rates) are due to differences in the corresponding controls. Despite SEM present a similar surface 605 
coverage of the controls, absorbance data indicate different biofilm biomass of the controls (Figure 2), 606 
most probably due to different biofilm thickness, not properly appreciable at SEM. CLSM analysis 607 
carried out in a previous work demonstrated that the silicone coating with AC7BS expressed a 608 
detectable capacity in controlling Candida biofilm thickness after 48 h incubation (Ceresa et al., 2018). 609 
No clear effect on the production of extracellular matrix by Candida was noted following the silicone 610 
precoating with R89BS or SL18. Indeed, the comparative analysis of Candida biofilm on the pre-611 
coated discs with the controls did not show major differences in the amount of extracellular matrix.  612 
However, it has to be taken into account that SEM imaging in high vacuum brought to significant 613 
collapse of the matrix volume, limiting the sensitivity of this technique in revealing small changes in 614 
the matrix.  615 
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The strong association of S. aureus and C. albicans was indeed found in both untreated controls and 616 
pre-coated surfaces demonstrating the ability of Candida to provide an anchoring support for S. aureus. 617 
The antibiofilm effect of the tested biosurfactants could be therefore mainly related to the antiadhesive 618 
properties rather than to a change in the microbial phenotypes including a reduction of the extracellular 619 
matrix production as reported by Gupta et al. (2019) using cholic acid-peptide conjugates. 620 
Furthermore, the use of R89BS and SL18 as coating agents did not result in a clear modification of the 621 
C. albicans hyphal morphology. However, it would be interesting to evaluate in further future whether 622 
these BSs, both in their free soluble and coated form, are able to cause a delay on Candida yeast-to 623 
hyphal transition at the initial phases of biofilm formation, thus as reported for sophorolipids from 624 
Starmerella bombicola MTCC1910 (Haque et al., 2016) and a L. rhamnosus (Tan et al., 2017). 625 
Another important aspect is the biocompatibility of the AC7BS-, R89BS- and SL18-coated silicone 626 
discs. It has been previously demonstrated that at concentrations lower than or equal to 0.2 mg/ml for 627 
R89BS and 0.5 mg/ml for AC7BS were not cytotoxic for MRC5 cells monolayers (Ceresa et al., 2018; 628 
Ceresa et al., 2019a). In this work, additional evaluations revealed no or negligible cytotoxicity on 629 
HaCaT cells when exposed to the BSs-coated discs eluates for up to 72 hours, paving the way for 630 
further investigation towards future in vivo applications. 631 
 632 
Conclusion 633 
In the present work, the activities of different biosurfactants against yeast and bacterial biofilms were 634 
demonstrated realizing a polymicrobial biofilm model able to support the growth of bacterial-fungal 635 
biofilms. The tests were conducted both under co-incubation and pre-coating conditions to evaluate, 636 
on the one hand, the inhibitory effect of BSs in solution against the polymicrobial biofilms and, on the 637 
other hand, the effectiveness of BSs as coating agents of medical devices to limit microbial infection. 638 
Biosurfactants successfully limited the formation of polymicrobial biofilms up to three days under both 639 
experimental conditions.  640 
The obtained results, together with the non-toxic nature of BSs at the tested concentrations and the 641 
biocompatibility of BSs-coated discs, further support the idea of a possible applicability of these natural 642 
molecules in the biomedical field. In particular, BSs-coating might be a promising strategy, supporting 643 
preventative infection measures and antimicrobial therapy, to reduce implant colonization and mitigate 644 
infections, thus prolonging the lifetime of implantable medical devices. 645 
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TABLE 1. Inhibition percentages of dual-species C. albicans - S. aureus and C. albicans - S. 912 
epidermidis biofilm formation on polystyrene in co-incubation assays. The anti-biofilm activity of BSs 913 
in free soluble form was detected by CV (Biofilm biomass) and MTT assays (Biofilm metabolic 914 
activity). 915 
Strains Assessment Time (h) Treatment 
   AC7BS (%) R89BS (%) 
C - Sa Biofilm biomass  24 96.4 95.6 
  48 85.8 96.2 
  72 84.3 94.3 
 Biofilm metabolic activity  24 95.0 96.4 
  48 89.2 96.1 
  72 83.0 93.5 
C - Se Biofilm biomass  24  96.5 
  48  96.5 
  72  95.7 
 Biofilm metabolic activity 24  95.1 
  48  94.6 
  72  95.3 
C - Sa: C. albicans - S. aureus  916 
C - Se: C. albicans - S. epidermidis 917 
: not evaluated 918 
 919 
TABLE 2. Inhibition percentages of dual-species C. albicans - S. aureus and C. albicans - S. 920 
epidermidis biofilm formation on BSs treated silicone discs by CV (Biofilm biomass) and MTT assays 921 
(Biofilm metabolic activity). 922 
Strains Assessment Time (h) Treatment 
   AC7BS (%) R89BS (%) SL18 (%) 
C - Sa Biofilm biomass  24 95.1 96.9 95.6 
  48 90.2 96.7 91.8 
  72 87.3 94.6 93.1 
 Biofilm metabolic activity  24 95.6 97.2 95.8 
  48 90.0 96.3 92.6 
  72 82.8 92.0 90.3 
C - Se Biofilm biomass  24  96.1 94.4 
  48  97.7 86.1 
  72  91.0 78.8 
 Biofilm metabolic activity 24  96.5 94.5 
  48  94.1 86.7 
  72  89.8 74.4 
C - Sa: C. albicans - S. aureus  923 
C - Se: C. albicans - S. epidermidis 924 
: not evaluated 925 
 926 
 927 
                                                                      Biosurfactants Against Polymicrobial Biofilms  
 
24 
This is a provisional file, not the final typeset article 
TABLE 3. Percentage (%) composition of C. albicans - S. aureus dual-species biofilms on the surface 928 
of silicone discs. 929 
Time (h) Strain Treatment 
  CTRL (%) AC7BS (%) R89BS (%) SL18 (%) 
24  C. albicans 1.4  4.5  4.9  4.0  
 S. aureus 98.6  95.5  95.1  96.0  
48  C. albicans 1.4  1.6  1.7  0.9  
  S. aureus 98.6  98.4  98.3  99.1  
72  C. albicans 1.3  1.4  0.3  0.5  
 S. aureus 98.7  98.6  99.7  99.5  
 930 
TABLE 4. Percentage (%) composition of C. albicans - S. epidermidis dual-species biofilms on the 931 
surface of silicone discs. 932 
Time (h) Strain Treatment 
  CTRL (%) R89BS (%) SL18 (%) 
24  C. albicans 0.2  1.0  0.6  
 S. epidermidis 99.8  99.0  99.4  
48  C. albicans 0.2  0.2  0.1  
 S. epidermidis 99.8  99.8  99.9  
72  C. albicans 0.2  0.2  0.2  
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FIGURE 1: Mono- and dual-species C. albicans - Staphylococcus spp. biofilm formation on 945 
polystyrene. The ability of microbial strains to form biofilms was evaluated at 24h, 48h and 72h by 946 
biofilm biomass (A, C) and biofilm metabolic activity (B, D) quantification. 947 
 948 
FIGURE 2: Mono- and dual-species C. albicans - Staphylococcus spp. biofilm formation on 949 
silicone discs. Biofilms were evaluated in terms of biofilm biomass (A, C) and biofilm metabolic 950 
activity (B, D) at 24h, 48h and 72h. 951 
 952 
FIGURE 3: Activity of BSs in free soluble form on C. albicans, S. aureus and S. epidermidis 953 
biofilm formation. The anti-biofilm activity of AC7BS and R89BS was evaluated in co-incubation 954 
conditions by the determination of biofilm biomass. 955 
 956 
FIGURE 4: Anti-biofilm activity of BSs in free soluble form on C. albicans - S. aureus and C. 957 
albicans - S. epidermidis biofilm formation. The anti-biofilm activity of BSs was evaluated in co-958 
incubation conditions in terms of biofilm biomass (A, D) and biofilm metabolic activity (B, E). The 959 
viability of planktonic cells (C, F) was measured by the metabolic activity assay.  960 
 961 
FIGURE 5: Anti-biofilm activity of the BSs coated silicone discs. The efficacy of the surface 962 
treatments was evaluated in terms of biofilm biomass (A, D) and biofilm metabolic activity (B, E). The 963 
viability of planktonic cells was measured by the metabolic activity assay (C, F).  964 
 965 
FIGURE 6: Anti-adhesive activity of the BSs coated silicone discs. The efficacy of the BSs surface 966 
treatment was evaluated in terms of C. albicans - S. aureus (A) and C. albicans - S. epidermidis (B) 967 
adherent cells after 4h of incubation. 968 
 969 
FIGURE 7: Changes in cell surface hydrophobicity and membrane permeability induced by free 970 
soluble BSs. Cell surface hydrophobicity (A) and membrane permeability (B) of C. albicans, S. aureus 971 
and S. epidermidis treated with BSs in free soluble form (co-incubation conditions), compared to 972 
control samples.  973 
 974 
FIGURE 8: Scanning electron microscopy images of the dual-species biofilms formed on the 975 
silicone discs surface at 72h. C. albicans - S. aureus on the left column, C. albicans - S. epidermidis 976 
on the right column. Different surface pre-coating treatments are presented: untreated controls (top 977 
row), rhamnolipid R89BS (middle raw) and sophorolipid SL18 (bottom row) treated discs. Insets 978 
present a lower magnification of the corresponding image to appreciate both macrostructural 979 
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arrangement of the biofilm on the surface and micro-structural architecture of the two species in each 980 
biofilm sample. Original magnification: 4000x (1000x for the insets). 981 
 982 
 983 
 984 
